Skip Navigation



Annals of Oncology Advance Access published online on October 30, 2006
Annals of Oncology, doi:10.1093/annonc/mdl395
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/2/370    most recent
mdl395v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Morschhauser, F.
Right arrow Articles by Dumontet, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morschhauser, F.
Right arrow Articles by Dumontet, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received June 13, 2006
Revised September 6, 2006
Accepted September 14, 2006

original article

Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma

F. Morschhauser 1, S. Depil 1, E. Jourdan 2, M. Wetterwald 3, R. Bouabdallah 4, G. Marit 5, P. Solal-Céligny 6, C. Sebban 7, B. Coiffier 8, N. Chouaki 9, F. Bauters 1, and C. Dumontet 8 *

1 Service des Maladies du Sang, Lille, France
2 Service d'Hématologie, Nîmes, France
3 Service d'Hématologie, Dunkerque, France
4 Service d'Hématologie, Marseille, France
5 Service des Maladies du Sang, Bordeaux, France
6 Service Oncologie-Maladies du Sang, Le Mans, France
7 Centre Léon Bérard, Lyon, France
8 Service d'Hématologie, Pierre Bénite, France
9 Eli Lilly, Paris, France

* To whom correspondence should be addressed.
C. Dumontet, E-mail: charles.dumontet{at}chu-lyon.fr


  Abstract

Single-agent gemcitabine has shown encouraging results in patients with mantle cell lymphoma (MCL). This phase II study further explored the potential of a gemcitabine-based regimen in patients with relapsed or refractory MCL. Patients <70 years old received the PDG regimen: gemcitabine (1000 mg/m2, days 1 and 8), dexamethasone (40 mg/m2, days 1-4), and cisplatin (100 mg/m2, day 1). Patients ≥70 years of age received dexamethasone and gemcitabine only (DG regimen). Thirty patients (12 in the DG group, 18 in the PDG group) with a median age 66.5 years (range, 47-81) received a median of six cycles in both groups. The overall response rate was 36.4% [95% confidence interval (CI), 15.2% to 64.6%] with the DG regimen and 44.4% (95% CI 24.6% to 66.3%) with the PDG regimen. The median progression-free survival was 3 months (95% CI 0.0-7.9) in the DG group and 8.5 months (95% CI 4.8-12.2) in the PDG group. With a median follow-up of 38.8 months, 13 patients (including 11 given PDG) are still alive. DG was well tolerated, and thrombocytopenia was the most prevalent toxicity in patients receiving PDG. Both regimens deserve to be further investigated as a backbone for combination chemotherapy in patients with MCL.

Keywords: cisplatin; dexamethasone; gemcitabine; mantle cell lymphoma.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
M. Ghielmini and E. Zucca
How I treat mantle cell lymphoma
Blood, August 20, 2009; 114(8): 1469 - 1476.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.